Secondary acute myeloblastic leukemia after adjuvant chemotherapy and radiotherapy in breast cancer: A case report

https://doi.org/10.19106/JMedScie004603201405

Mardiah Suci Hardianti(1*), Johan Kurnianda(2), Kartika Widayati Taroeno-Hariadi(3)

(1) Division of Hematology-Medical Oncology, Department of Internal Medicine, Dr. Sardjito General Hospital/ Faculty of Medicine Universitas Gadjah Mada, Yogyakarta, Indonesia
(2) Division of Hematology-Medical Oncology, Department of Internal Medicine, Dr. Sardjito General Hospital/ Faculty of Medicine Universitas Gadjah Mada, Yogyakarta, Indonesia
(3) Division of Hematology-Medical Oncology, Department of Internal Medicine, Dr. Sardjito General Hospital/ Faculty of Medicine Universitas Gadjah Mada, Yogyakarta, Indonesia
(*) Corresponding Author

Abstract


A rising number of long-term survivors and potential long-term outcome related to the treatment is
one of the most important issue due to the advances of management in cancer. The development of
secondary malignancy has been reported in a number of cohorts. We present a case of breast cancer
patient developing acute myeloid leukemia (AML)- M5 within a relatively short interval of two and a
half years from her primary treatment with adjuvant chemotherapy with 4 cycles of doxorubicin and
cyclophosphamide, followed by 4 cycles of three weekly paclitaxel (AC-T) and radiotherapy. What
could be attributed to the occurrence of secondary leukemia in this patient will be discussed.

Keywords


breast cancer- secondary leukemia- adjuvant chemotherapy-radiotherapy-breast cancer

Full Text:

PDF



DOI: https://doi.org/10.19106/JMedScie004603201405

Article Metrics

Abstract views : 354 | views : 374




Copyright (c) 2015 Journal of the Medical Sciences (Berkala ilmu Kedokteran)



      

Creative Commons License
Journal of the Medical Sciences (Berkala Ilmu Kedokteran) by  Universitas Gadjah Mada is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Based on a work at http://jurnal.ugm.ac.id/bik/.